FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2121-2123 May 20, 2004 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

On September 30, 2003, Boston University and the University of Texas at Galveston were each awarded $120 million by the National Institute of Allergy and Infectious Diseases to build a biosafety level 4 laboratory. Nine regional biocontainment laboratories were funded along with these two national biocontainment laboratories. In announcing the awards, Secretary of Health and Human Services Tommy Thompson described them as "a major step towards being able to provide Americans with effective therapies, vaccines and diagnostics for diseases caused by agents of bioterror as well as for naturally occurring emerging infections."¹

(Figure)

View larger version (68K): [in this window] [in a new window]   Figure. CDC Researchers in a . . . [Full Text of this Article]

 

Source Information

From the Radcliffe Institute for Advanced Study, Cambridge, Mass.

This article has been cited by other articles:

• Steinbrook, R. (2006). Research in the Hot Zone. NEJM 354: 109-112 [Full Text]